Search

Marianne P. Allen

Examiner (ID: 17617, Phone: (571)272-0712 , Office: P/1647 )

Most Active Art Unit
1647
Art Unit(s)
1818, 1812, 1645, 1805, 1631, 1647
Total Applications
2168
Issued Applications
1046
Pending Applications
251
Abandoned Applications
885

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18537483 [patent_doc_number] => 20230242576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN [patent_app_type] => utility [patent_app_number] => 17/990507 [patent_app_country] => US [patent_app_date] => 2022-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990507 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/990507
METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN Nov 17, 2022 Abandoned
Array ( [id] => 18451559 [patent_doc_number] => 20230192837 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/054284 [patent_app_country] => US [patent_app_date] => 2022-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14140 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054284 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/054284
HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODIES Nov 9, 2022 Pending
Array ( [id] => 18212462 [patent_doc_number] => 20230058726 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => CHEMOPREVENTION USING CONTROLLED- RELEASE FORMULATIONS OF ANTI-INTERLEUKIN 6 AGENTS, SYNTHETIC VITAMIN A ANALOGUES OR METABOLITES, AND ESTRADIOL METABOLITES [patent_app_type] => utility [patent_app_number] => 17/977691 [patent_app_country] => US [patent_app_date] => 2022-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16126 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17977691 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/977691
CHEMOPREVENTION USING CONTROLLED- RELEASE FORMULATIONS OF ANTI-INTERLEUKIN 6 AGENTS, SYNTHETIC VITAMIN A ANALOGUES OR METABOLITES, AND ESTRADIOL METABOLITES Oct 30, 2022 Pending
Array ( [id] => 18657750 [patent_doc_number] => 20230303704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => FGFR3 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/045995 [patent_app_country] => US [patent_app_date] => 2022-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44228 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045995 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/045995
FGFR3 ANTIBODIES AND METHODS OF USE Oct 11, 2022 Pending
Array ( [id] => 18310223 [patent_doc_number] => 20230114123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => METHOD OF STIMULATING ASYMMETRIC DIVISION OF SATELLITE STEM CELLS [patent_app_type] => utility [patent_app_number] => 17/961502 [patent_app_country] => US [patent_app_date] => 2022-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9689 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17961502 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/961502
METHOD OF STIMULATING ASYMMETRIC DIVISION OF SATELLITE STEM CELLS Oct 5, 2022 Abandoned
Array ( [id] => 20645821 [patent_doc_number] => 12600756 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-14 [patent_title] => Recombinant modified fibroblast growth factors and therapeutic uses thereof [patent_app_type] => utility [patent_app_number] => 17/939238 [patent_app_country] => US [patent_app_date] => 2022-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 30125 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17939238 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/939238
Recombinant modified fibroblast growth factors and therapeutic uses thereof Sep 6, 2022 Issued
Array ( [id] => 19816798 [patent_doc_number] => 20250075005 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => USE OF ALPHA-ENOLASE ANTAGONIST IN TREATING OF FIBROTIC DISEASES [patent_app_type] => utility [patent_app_number] => 18/292352 [patent_app_country] => US [patent_app_date] => 2022-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5340 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18292352 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/292352
USE OF ALPHA-ENOLASE ANTAGONIST IN TREATING OF FIBROTIC DISEASES Aug 18, 2022 Pending
Array ( [id] => 18257437 [patent_doc_number] => 20230084477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASE [patent_app_type] => utility [patent_app_number] => 17/818798 [patent_app_country] => US [patent_app_date] => 2022-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818798 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/818798
COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASE Aug 9, 2022 Abandoned
Array ( [id] => 19989672 [patent_doc_number] => 20250127894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-24 [patent_title] => PROCESS FOR PRODUCING ARMED IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 18/682632 [patent_app_country] => US [patent_app_date] => 2022-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18682632 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/682632
PROCESS FOR PRODUCING ARMED IMMUNE CELLS Aug 9, 2022 Pending
Array ( [id] => 18536100 [patent_doc_number] => 20230241187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => Lysosomal Targeting Peptides and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/815468 [patent_app_country] => US [patent_app_date] => 2022-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815468 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/815468
Lysosomal Targeting Peptides and Uses Thereof Jul 26, 2022 Pending
Array ( [id] => 19800516 [patent_doc_number] => 20250066441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/580810 [patent_app_country] => US [patent_app_date] => 2022-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97868 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18580810 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/580810
IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF Jul 17, 2022 Pending
Array ( [id] => 19543153 [patent_doc_number] => 20240360189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => DIMERIC PROTEIN COMPLEXES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/577400 [patent_app_country] => US [patent_app_date] => 2022-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18577400 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/577400
DIMERIC PROTEIN COMPLEXES AND USES THEREOF Jul 10, 2022 Pending
Array ( [id] => 19417423 [patent_doc_number] => 20240293546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => D2C7 EGFR AND EGFR VIII BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS AND METHODS OF MAKING AND USING SAME [patent_app_type] => utility [patent_app_number] => 18/574656 [patent_app_country] => US [patent_app_date] => 2022-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18574656 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/574656
D2C7 EGFR AND EGFR VIII BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS AND METHODS OF MAKING AND USING SAME Jun 30, 2022 Pending
Array ( [id] => 18420180 [patent_doc_number] => 20230174641 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => ANTI-ACTH ANTIBODIES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/850135 [patent_app_country] => US [patent_app_date] => 2022-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 136003 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850135 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/850135
Anti-ACTH antibodies and use thereof Jun 26, 2022 Issued
Array ( [id] => 20158223 [patent_doc_number] => 12384835 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Cysteine linked nanobody dimers [patent_app_type] => utility [patent_app_number] => 17/850339 [patent_app_country] => US [patent_app_date] => 2022-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 14 [patent_no_of_words] => 26808 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 205 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850339 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/850339
Cysteine linked nanobody dimers Jun 26, 2022 Issued
Array ( [id] => 18004984 [patent_doc_number] => 20220363750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => ARTHRITIS TREATMENT [patent_app_type] => utility [patent_app_number] => 17/807939 [patent_app_country] => US [patent_app_date] => 2022-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17807939 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/807939
Arthritis treatment Jun 20, 2022 Issued
Array ( [id] => 18004977 [patent_doc_number] => 20220363743 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => ANTI-ANGPT2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/842904 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24145 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842904 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/842904
ANTI-ANGPT2 ANTIBODIES Jun 16, 2022 Abandoned
Array ( [id] => 18093173 [patent_doc_number] => 20220411514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE [patent_app_type] => utility [patent_app_number] => 17/834703 [patent_app_country] => US [patent_app_date] => 2022-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68867 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17834703 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/834703
ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE Jun 6, 2022 Pending
Array ( [id] => 19855588 [patent_doc_number] => 12258411 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Anti-CCR8 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/831398 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 13 [patent_no_of_words] => 48637 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831398 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/831398
Anti-CCR8 antibodies and uses thereof Jun 1, 2022 Issued
Array ( [id] => 17988897 [patent_doc_number] => 20220354934 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => Lysosomal Targeting Peptides and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/829620 [patent_app_country] => US [patent_app_date] => 2022-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15486 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17829620 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/829620
Lysosomal Targeting Peptides and Uses Thereof May 31, 2022 Pending
Menu